Liraglutide overview
Daily GLP-1 receptor agonist. Brand names: Victoza (T2D), Saxenda (chronic weight management). Older agent, lower weight loss than semaglutide or tirzepatide.
Liraglutide at a glance
Related pages
- Clinical research overview
- Compare GLP-1 forms
- Compounded vs brand
- NexLife (highest v4.1 score)
Key facts, checked November 20, 2026
Liraglutide is sold as Victoza for type 2 diabetes and Saxenda for weight management. The Saxenda label covers adults and patients 12 and older weighing more than 60 kg with obesity, as a once-daily injection; the Victoza label covers type 2 diabetes from age 10. In the liraglutide adolescent trial (NEJM 2020), 43.3% of teens on liraglutide 3.0 mg cut their BMI by at least 5%, against 18.7% on placebo. FDA drug-shortage data (openFDA) still list liraglutide injection as in shortage, with an update dated October 14, 2026.